title: Specific deficiency of p56lck expression in T lymphocytes from type 1 diabetic patients.
abstract: Peripheral T lymphocyte activation in response to TCR/CD3 stimulation is reduced in type 1 diabetic patients. To explore the basis of this deficiency, a comprehensive analysis of the signal transduction pathway downstream of the TCR/CD3 complex was performed for a cohort of patients (n = 38). The main result of the study shows that T cell hyporesponsiveness is positively correlated with a reduced amount of p56(lck) in resting T lymphocytes. Upon CD3-mediated activation, this defect leads to a hypophosphorylation of the CD3zeta-chain and few other polypeptides without affecting the recruitment of ZAP70. Other downstream effectors of the TCR/CD3 transduction machinery, such as phosphatidylinositol 3-kinase p85alpha, p59(fyn), linker for activation of T cells (LAT), and phospholipase C-gamma1, are not affected. In some patients, the severity of this phenotypic deficit could be linked to low levels of p56(lck) mRNA and resulted in the failure to efficiently induce the expression of the CD69 early activation marker. We propose that a primary deficiency in human type 1 diabetes is a defect in TCR/CD3-mediated T cell activation due to the abnormal expression of the p56(lck) tyrosine kinase.
authors.affiliation: UPRES-EA2193, Institut Fédiratif de Recherche 35, Physiopathologie Métabolique et Nutritionnelle, Université de la Méditerranée, Centre Hospitalier Universitaire Timone, Marseille, France.
authors.forename: S
authors.initials: S
authors.lastname: Nervi
authors.forename: C
authors.initials: C
authors.lastname: Atlan-Gepner
authors.forename: B
authors.initials: B
authors.lastname: Kahn-Perles
authors.forename: P
authors.initials: P
authors.lastname: Lecine
authors.forename: B
authors.initials: B
authors.lastname: Vialettes
authors.forename: J
authors.initials: J
authors.lastname: Imbert
authors.forename: P
authors.initials: P
authors.lastname: Naquet
mesh_terms: D000293:Adolescent; D000328:Adult; D015331:Cohort Studies; D003922:Diabetes Mellitus, Type 1 / Q000201:enzymology* / Q000235:genetics*; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007108:Immune Tolerance / Q000235:genetics; D007399:Interphase / Q000235:genetics / Q000276:immunology; D007963:Leukocytes, Mononuclear / Q000201:enzymology / Q000276:immunology; D008213:Lymphocyte Activation / Q000235:genetics; D019860:Lymphocyte Specific Protein Tyrosine Kinase p56(lck) / Q000096:biosynthesis* / Q000172:deficiency* / Q000235:genetics / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010766:Phosphorylation; D019000:Phosphotyrosine / Q000378:metabolism; D012333:RNA, Messenger / Q000096:biosynthesis; D017260:Receptor-CD3 Complex, Antigen, T-Cell / Q000502:physiology; D016176:T-Lymphocyte Subsets / Q000201:enzymology* / Q000378:metabolism
chemical_list: D012333:RNA, Messenger; D017260:Receptor-CD3 Complex, Antigen, T-Cell; D019000:Phosphotyrosine; D019860:Lymphocyte Specific Protein Tyrosine Kinase p56(lck)